\n\n\n\n

CAS number<\/a><\/th>\n

136790-76-6<\/a>^{\u00a0<\/sup><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nSucampo Pharmaceuticals, Inc. and Abbott today announced the availability of AMITIZA^{\u00ae<\/sup>\u00a0(lubiprostone) in Japan, a prescription medicine for the treatment of chronic constipation not caused by organic diseases. AMITIZA was approved by the Ministry of Health, Labor and Welfare (MHLW) in Japan in June.<\/p>\n}}

\u201cChronic constipation is a medical condition affecting several million people in Japan and is one of the most common digestive condition complaints. Healthcare providers will now have a prescription option to help treat this condition more effectively and longer term, compared to currently approved over-the-counter medications\u201d<\/p><\/blockquote>\n
\u201cMillions of patients in Japan have been suffering from chronic constipation, without efficacious and well-tolerated, long-term treatment options. We are pleased to bring AMITIZA\u2019s experience of six years and over six million prescriptions in the United States to the Japanese market, to benefit the healthcare providers and patients who need it,\u201d says Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo\u2019s Chairman and Chief Executive Officer.<\/p>\n
\u201cChronic constipation is a medical condition affecting several million people in Japan and is one of the most common digestive condition complaints. Healthcare providers will now have a prescription option to help treat this condition more effectively and longer term, compared to currently approved over-the-counter medications,\u201d says Akihiko Honda, General Manager, Abbott Japan.<\/p>\n
AMITIZA may significantly advance the treatment of chronic constipation and will be the only prescription option available in Japan for this condition. The medicine is the world\u2019s first chloride channel activator approved for therapeutic use, and has a unique mode of action that induces natural bowel movement frequency that is more in line with normal bowel habits.<\/p>\n
7-[(1R<\/em>,3R<\/em>,6R<\/em>,7R<\/em>)-3-(1,1-difluoropentyl)-3-hydroxy-
\n8-oxo-2-oxabicyclo[4.3.0]non-7-yl]heptanoic acid<\/p>\n
$\"\"$ <\/p>\n
Lubiprostone<\/strong>\u00a0(rINN<\/a>, marketed under the trade name\u00a0Amitiza<\/strong>) is a\u00a0medication<\/a>used in the management of\u00a0 chronic<\/a>\u00a0 idiopathic<\/a>\u00a0 constipation<\/a>\u00a0and\u00a0 irritable bowel syndrome<\/a>. It was approved by the U.S.\u00a0 Food and Drug Administration<\/a>\u00a0(FDA) for this purpose on 31 January 2006.<\/p>\n
Lubiprostone is used for the treatment of chronic\u00a0 constipation<\/a>\u00a0of unknown cause and\u00a0 irritable bowel syndrome<\/a>\u00a0associated with constipation.[1]<\/a><\/sup><\/p>\n
As of 20 July 2006, Lubiprostone had not been studied in children. There is current research underway to determine the efficacy in postoperative bowel dysfunction, and\u00a0 opioid<\/a>-induced bowel dysfunction.<\/p>\n
http:\/\/www.amitiza.com\/<\/a><\/p>\n
$\"Lubiprostone.png\"$ <\/p>\n
<\/p>\n
Sobrera, L. A.; Castaner, J. (2004).\u00a0Drugs of the Future<\/em>\u00a029<\/strong>\u00a0(4): 336.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"
Sucampo and Abbott Announce Launch of AMITIZA in Japan Product is Japan\u2019s\u00a0Only\u00a0Prescription Medicine for Chronic Constipation Lubiprostone CAS number 136790-76-6\u00a0 Sucampo Pharmaceuticals, Inc. and Abbott today announced the availability of AMITIZA\u00ae\u00a0(lubiprostone) in Japan, a prescription medicine for the treatment of chronic constipation not caused by organic diseases. AMITIZA was approved by the Ministry of Health,… Continue reading Sucampo and Abbott Announce Launch of AMITIZA in Japan, 26 nov 2012<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[144],"_links":{"self":[{"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/posts\/264"}],"collection":[{"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/comments?post=264"}],"version-history":[{"count":2,"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/posts\/264\/revisions"}],"predecessor-version":[{"id":266,"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/posts\/264\/revisions\/266"}],"wp:attachment":[{"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/media?parent=264"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/categories?post=264"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/tags?post=264"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}